Summary
Becton Dickinson & Co. (BDX) reported solid performance for the quarter ended June 30, 2014, with revenues increasing by 5.1% to $2.157 billion, driven by growth in the Medical and Biosciences segments. The company maintained a strong financial position, with cash flows from operating activities totaling $1.207 billion for the nine-month period and $2.6 billion in cash and short-term investments at quarter-end. Diluted earnings per share from continuing operations saw a notable increase to $1.65 compared to $1.47 in the prior year's quarter, reflecting operational improvements and favorable segment performance. Despite some challenges in the U.S. Diagnostics segment due to ongoing weakness in the Women's Health and Cancer platform, overall revenue growth was bolstered by international sales and strong performance in emerging markets. The company continued to return value to shareholders through share repurchases and dividends, underscoring a commitment to financial discipline and shareholder returns. While facing some ongoing litigation and economic uncertainties, BDX demonstrated resilience and strategic focus on core business expansion and innovation.
Financial Highlights
49 data points| Revenue | $2.16B |
| Cost of Revenue | $1.05B |
| Gross Profit | $1.11B |
| R&D Expenses | $137.00M |
| SG&A Expenses | $528.00M |
| Operating Expenses | $1.71B |
| Operating Income | $445.00M |
| Interest Expense | $33.00M |
| Net Income | $326.00M |
| EPS (Basic) | $1.69 |
| EPS (Diluted) | $1.65 |
| Shares Outstanding (Basic) | 193.05M |
| Shares Outstanding (Diluted) | 197.00M |
Key Highlights
- 1Revenue increased by 5.1% to $2.157 billion in the third quarter, primarily driven by the Medical and Biosciences segments.
- 2Diluted Earnings Per Share (EPS) from continuing operations rose to $1.65, up from $1.47 in the prior year's quarter, indicating improved profitability.
- 3Operating cash flow for the nine months ended June 30, 2014, was strong at $1.207 billion, demonstrating healthy cash generation.
- 4The company maintained a robust liquidity position with $2.6 billion in cash and short-term investments as of June 30, 2014.
- 5Shareholders received $316 million in dividends and $400 million in share repurchases during the first nine months of the fiscal year, highlighting a commitment to returning capital.
- 6International sales showed strong performance, growing 6.7% in the third quarter, with emerging markets continuing to be key growth drivers.
- 7The Medical segment reported a 5.3% revenue increase, driven by Medical Surgical Systems and Pharmaceutical Systems, while the Biosciences segment saw a 7.7% increase.